Investors & Media

Aceragen is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Our portfolio includes late-stage programs that we are developing to be innovative therapeutics capable of addressing the unmet medical needs of those individuals.

Featured Presentation

More information is coming soon.

Recent News

Aug 04, 2023
Aceragen, Inc. to Delist from The Nasdaq Stock Market Read More
May 30, 2023
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Read More
Feb 06, 2023
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study Read More


There are currently no events to display.